Andrew Warner: h-index, Total Citations, and Citation Map
Andrew Warner's h-index is 20 (20 i10-index, 39,819+ total citations across 20+ publications) according to Google Scholar as of July 2026.
Andrew Warner is a researcher affiliated with their institution, specializing in various fields. Their work has been cited 39,819 times. This profile visualizes their global influence, highlighting strong citation networks in China.
Andrew Warner's Citation Metrics
Bibliometric impact based on 20 indexed publications. Of these, 18 are original research articles — the rest are literature highlights, conference abstracts or theses.
- H-Index
- 20
- i10-Index
- 20
- Total Citations
- 39,819
- Citing Countries
- 31
As of July 2026.
Andrew Warner has an h-index of 20 and 39,819 total citations across 20 publications, with research cited by institutions in 31 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Andrew Warner's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
20191,808
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
7 citing papers could not be classified (no author data) — excluded from the percentages above.
The researcher pioneered randomized phase III trial protocols for stereotactic ablative radiotherapy in oligometastatic cancer, establishing a rigorous framework for comprehensive treatment of limited metastatic disease.
The researcher established the clinical efficacy of stereotactic ablative radiotherapy for oligometastatic cancers through a pivotal randomized phase 2 trial, fundamentally challenging standard palliative care paradigms.
The researcher established a predictive framework for esophagitis risk following chemoradiation in non-small cell lung cancer through a seminal individual patient data meta-analysis.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Andrew Warner's research
Their work has been cited 39,819 times across 20 publications (h-index 20), according to Google Scholar.
Their most-cited work, “Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial” (2019), has accumulated 1,808 citations. Other influential works include “Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial” (2020) with 1,204 citations and “Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial” (2019) with 453 citations.
Citations of Andrew Warner's research come primarily from China, United States and United Kingdom, reflecting international research impact across 5+ countries. The interactive citation map above shows the full geographic distribution of the institutions citing this work.
